Seattle Genetics hires new commercial chief, promotes legal exec
US biotechnology firm Seattle Genetics has appointed Bruce Seeley executive vice president, commercial. Mr. Seeley brings more than 18 years of experience in oncology drug marketing and sales to the company, most recently from Genentech BioOncology.
In addition, the company announced the promotion of Kirk Schumacher, who joined the firm in 2003, to vice president, legal affairs and compliance, and general counsel.
'Bruce will lead our efforts to build Seattle Genetics' marketing and sales functions as we position the company for commercial operations, including the planned 2011 product launch of brentuximab vedotin (SGN-35),' commented Clay Siegall, president and chief executive of Seattle Genetics. '
Mr Seeley previously worked at Genentech (a wholly- owned member of the Roche Group), most recently as senior director for Herceptin (trastuzumab) and T-DM1 marketing. Before that, he spent four years at Aventis Pharma in increasing roles of responsibility, said Seattle Genetics.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze